Kornimate/medical-research-clean huggingface dataset:
intercostal nerve block: efficacy of cinb for patients with multiple rib fractures

Conditions: Rib Fractures

Summary: this is a prospective, randomized, non-blinded study comparing cinb plus medical therapy versus standard medical care (non-steroidals and opioids intravenous/oral inpatient and oral outpatient) alone for patients with multiple rib fractures. the objective of this study is to analyze the effect of continuous intercostal nerve block (cinb) in the treatment of patients admitted to the adult trauma service with rib fractures. the effectiveness of cinb as adjunctive treatment will be compared to standard medical therapy involving nonsteroidal and intravenous/oral opioid medications.


Eligibility criteria:
inclusion criteria: * subjects will be at least 18 years old * subjects will have 2 or more identified rib fractures * subjects will be willing to provide informed consent for procedure * subjects will be identified as appropriate for initiation of continuous nerve block therapy for treatment of rib fracture associated pain. exclusion criteria: * documented allergy to study medication * epidural catheter use * prisoners * refusal of cinb therapy

Keywords: intercostal nerve block opioid non steroidal inpatient outpatient catheter anesthetic epidural
mixed presentation on social media

Conditions: Tobacco Use; Tobacco Dependence

Summary: this study is to understand how the presentation of information on social media influences processing and recall of information, particularly in relation to modified risk tobacco products. participants will see a social media site where either (a) the topic of discussion varies between each post or (b) posts on the same topic are grouped together. they will then be asked to recall information about the posts they saw on the site.


Eligibility criteria:
inclusion criteria: * must be a current or former smoker exclusion criteria: -

Keywords: modified risk tobacco products information recall tobacco tobacco use social media
self medication in odontology (aude)

Conditions: Dental Anxiety; Dental Pain

Summary: to describe and understand the self-medication behaviours of a population of adults coming to the clermont-ferrand dentistry department for acute pain of pulpal origin and of a population of adults coming to the specific care unit of the clermont-ferrand dentistry department or the riom hospital for treatment under general anaesthesia.

self-medication behaviour will be studied by means of a questionnaire. questionnaires on insecurity, anxiety about dental care, items related to the ingestion function of the international classification of functioning, disability and health (icf), a visual analogue pain assessment scale and the pcs-cf pain dramatisation scale will also be used.

Eligibility criteria:
inclusion criteria: * adult patient, male or female, coming to consult in the clermont-ferrand or riom hospital for acute pain of pulp origin and periapical or eligible for dental treatment under general anesthesia in a context phobic. * understanding and practicing french * giving informed consent to participate in research. * affiliation to a social security scheme. exclusion criteria: * patients under guardianship. * patient's refusal to participate in the study.

Keywords: anxiety pulpal pain self medication observational study
flumatinib versus nilotinib for newly diagnosed chronic phase chronic myeloid leukemia

Conditions: CML, Chronic Phase; TKI

Summary: the ultimate goal of cml treatment is to improve survival, including overall survival (os), progression-free survival (pfs), event-free survival (efs), and treatment-free remission (tfr). tfr is a new therapeutic goal for chronic myeloid leukemia in chronic phase (cml-cp). in enestnd and dasision trials, both nilotinib and dasatinib achieved dmr more effectively than imatinib. in the guidelines for diagnosis and treatment of chronic myeloid leukemia in china (2020 edition), flumatinib has been recommended as an appropriate first-line treatment for newly diagnosed chronic phase chronic myeloid leukemia (cml-cp) patients. there is no doubt that the second-generation tkis show great advantages in deep molecular response, which further increases the possibility of achieving treatment-free remission. however, there is no direct comparative study to determine which tki is better for de novo cml-cp. thus, we conducted a multi-center, open-lable and real world study to compare the efficacy and safety between flumatinib and nilotinib.


Eligibility criteria:
inclusion criteria: 1. male or female patients ≥18 years of age; 2. cml-cp patients diagnosed with cml within half a year；patients who have been using second-generation tki nilotinib or flumatinib for first-line treatment in clinical practice, but the history of continuous treatment does not exceed 3 months；3.patients are allowed to receive hydroxyurea treatment before first-line treatment with nilotinib or flumartinib; patients treated with interferon for no more than 3 months and other tkis for no more than 2 weeks; 4.patients who must sign informed consent before screening exclusion criteria: 1. t315i mutation ; y253f/h, e255k/v, f359c/v/i mutations in the nilotinib group; 2. entry into another therapeutic clinical trial; 3. concomitant diseases that, according to the investigator's judgment, pose a serious risk to the patient's safety or completion of the study; 4. history of neurological or psychiatric disorders, including epilepsy or dementia; 5. major surgery within 4 weeks prior to day 1 of study; 6. patients with another primary malignancy,unless the other primary malignancy is currently stable or does not need active intervention; 7. women of reproductive age or men who are unable to use adequate methods of contraception, including women who are pregnant or breastfeeding; 8. ecog≥3; 9. patients who are unable to compliance with study or follow-up procedures;
subthreshold laser treatment versus threshold laser treatment for symptomatic retinal arterial macroaneurysm

Conditions: Aneurysm

Summary: best treatment option of retinal arterial macroaneurysm is still controversial. a recent publication has shown that subthreshold laser treatment can be beneficial in improving visual acuity in eyes with symptomatic retinal arterial macroaneurysm. aim of the study is to compare the effects of subthreshold laser treatment and threshold laser treatment in patients affected by symptomatic retinal arterial macroaneurysm.

the treatment of ram is controversial and at present there is no general consensus about the best approach. spontaneous obliteration of ram may occur over the follow-up, but the long persistence of blood or subretinal fluid may lead to progressive photoreceptor damage, with consequent irreversible visual impairment. more specifically, the presence of subretinal hemorrhage beneath the fovea leads to a diminished visual function. treatment is generally indicated for ram associated with exudative manifestations involving the fovea which do not tend to resolve spontaneously. the most commonly employed approach is direct or indirect laser photocoagulation with visible end-point. nevertheless, several complications may be associated with conventional threshold laser for macular lesions, including enlargement of laser scar, choroidal neovascularization, and subretinal fibrosis. in addition to these complications, arteriolar obliteration, increased retinal exudation and scarring, with possible retinal traction, have also been reported as possible sequelae of the laser photocoagulation of ram. another approach for the treatment of ram is based on the use of subthreshold laser treatment. subthreshold laser treatment has been proposed in an attempt to minimize the negative aspects of conventional grid laser photocoagulation and has achieved encouraging results, especially in macular oedema secondary to diabetic retinopathy, proliferative diabetic retinopathy, and branch retinal vein occlusion. the concept underlying the use of subthreshold laser treatment is to decrease the laser damage by reducing the duration of laser exposure and by using a subvisible clinical end point. a micropulse diode laser releases low energy micropulses in order to confine the energy to the rpe cells, with limited protein denaturation, avoiding lateral thermal spreading. aim of the study is to compare the effects of subthreshold laser treatment to those of threshold laser treatment in patients affected by symptomatic retinal arterial macroaneurysm.

Eligibility criteria:
inclusion criteria: * retinal arterial macroaneurysm, exudative manifestations involving the fovea (including: subretinal/intraretinal fluid, and/or hard exudates, and/or hemorrhages), best corrected visual acuity worse than 20/80 snellen equivalent, corresponding to 0.6 logmar exclusion criteria: * previous treatments for retinal arterial macroaneurysm, any other ocular disease

Keywords: retinal arterial macroaneurysm laser treatment
optimizing surgical decisions in young adults with breast cancer

Conditions: Breast Cancer Stage 0; Breast Cancer Stage I; Breast Cancer Stage II; Breast Cancer Stage III

Summary: the goal of this study is to understand and improve the breast surgical decision-making process for young women newly diagnosed with breast cancer. as part of this study, the investigators will evaluate the impact and use a web-based tool called consyder that is designed to provide useful information to young breast cancer patients. it is also meant to improve communication between young women and their surgeons with the purpose of helping patients make appropriate surgical decisions. participants will complete surveys approximately within 1 week of the surgical consult and approximately 6 months after surgery. patients who receive neoadjuvant chemotherapy will also be surveyed after the completion of neoadjuvant treatment but prior to surgery. some patients will be invited for an interview after their surgery as part of the evaluation. a subset of patients/surgeons will also have their surgical consultation audio-recorded.

primary objectives: * to test the effectiveness of the consyder decision support tool on reducing decisional conflict prior to breast cancer surgery. * to evaluate the implementation of and mechanisms of use for consyder. secondary objectives: * to determine the impact of consyder on decision-making preferences, breast cancer knowledge, treatment goals and preferences, anxiety, decisional regret, and self-efficacy in communication. exploratory objectives: * to explore whether consyder impacts surgical choice. outline: this is a multi-site cluster randomized trial using a stepped wedge design. approximately 800 women will be recruited at 4 study sites (weill cornell medicine, yale cancer center, dana-farber cancer institute, duke cancer institute), including network affiliate sites, over an approximate 30-month period. all sites will have a 6-month "run-in" period where patients will not be sent consyder. the 6-month blocks may be extended if recruitment targets are not met. sites will be randomized to begin delivery of consyder to all newly diagnosed women, age ≤44, with stage 0-iii breast cancer as part of routine clinical care; young women will have access to the website whether or not they consent to research study participation.

Eligibility criteria:
inclusion criteria: * female aged 18-44 * new diagnosis of stage 0, 1, 2, or 3 unilateral breast cancer * english or spanish speaking exclusion criteria: * diagnosis of de novo stage 4 breast cancer * recurrent early-stage breast cancer * bilateral breast cancer
cervical cancer screening intervention among korean american women

Conditions: Cervical Carcinoma

Summary: this is a randomized trial to evaluate the effects of a community-based intervention on increasing cervical cancer screening rates in underserved korean american women. due to the multiple factors that contribute to screening uptake, an educational program customized to korean culture combined with navigation assistance may be effective in increasing the number of korean american women who can access cervical cancer screening.

primary objectives: i. to evaluate the efficacy of a culturally-appropriate educational intervention compared to a general cancer health education program in increasing cervical cancer screening among korean american women. secondary objectives: i. to examine the effects of a culturally-appropriate intervention on women's knowledge, psychosocial beliefs about cervical cancer and screening, and barriers to screening compared to a general cancer health education program. ii. to examine the extent to which changes in knowledge, psychosocial beliefs, and barriers mediate the effects of the intervention on screening behavior. outline: participants are randomized to 1 of 2 arms. arm i (intervention condition): participants undergo a culturally appropriate, church-based intervention comprised of four components: 2-hour small group education sessions delivered at church sites by professional, bilingual community health educators (ches) that include culturally appropriate visual aids and print materials in korean; navigation assistance, including language services, appointment scheduling, and transportation assistance from ches and church health workers (chws); referrals to pap test sites; and a 6-month reminder letter for screening. arm ii (control condition): participants undergo 2-hour general health and cancer education by bilingual ches, which covers nutrition, regular check-ups, tobacco use, and cancer screening. participants also receive pre-existing written material produced by the american cancer society (acs), national institutes of health (nih), and centers for disease control (cdc)., and are advised to seek regular preventive health services. after completion of study, participants are followed up post-intervention and at 12 months.

Eligibility criteria:
inclusion criteria: * self-identified korean ethnicity * possessing a functional telephone in the home or on person * anticipated presence in this geographic region for a period of one year exclusion criteria: * a current diagnosis of cervical cancer * have had a pap test within the past 12 months * are currently adherent to doctor recommended screening interval
treatment protocol of plozasiran in adults with fcs

Conditions: Familial Chylomicronemia

Summary: this is a treatment program for the use of plozasiran in adults with familial chylomicronemia syndrome (fcs). the program will enroll eligible patients ≥18 years of age, with fasting triglycerides ≥880 mg/dl (≥10 mmol/l) that is not adequately controlled with standard lipid-lowering therapy, and with a diagnosis of fcs. patients will receive 25 mg of plozasiran by subcutaneous (sc) injection on day 1 and every three months for a total of 5 injections. the duration of the program is 15 months.


Eligibility criteria:
inclusion criteria: * fasting triglycerides (tg) ≥ 880mg/dl that is not sufficiently controlled on standard lipid-lowering therapy * established diagnosis of fcs based on documented history of fasting tg levels in excess of 1000 mg/dl on repeated testing (for at least 3 prior occasions), and at least one of the following: a supportive genetic test, documented history of recurrent episodes of acute pancreatitis not caused by alcohol or cholelithiasis, documented history of recurrent hospitalizations for severe abdominal pain without other explainable cause, documented history of childhood pancreatitis, family history of hypertriglyceridemia-induced pancreatitis * willing to follow dietary counseling based on local standard of care, consistent with an intake of ≤ 20 g of fat per day * if on medications for management of type 2 diabetes the dosing regimen must be stable. * participants of childbearing potential must agree to use a highly effective form of contraception in addition to a male condom during the program and for at least 90 days after the last dose of plozasiran exclusion criteria: * diabetes mellitus with any of the following at day 1: newly diagnosed within the past 24 weeks, hba1c ≥9.0% within the past 4 weeks, meaningful medical events relating to poor glycemic control, changes in basal insulin regimen of more than =/- 10 units within 12 weeks if insulin-dependent * history of acute coronary syndrome events * new york heart association class iii or iv heart failure or last known ejection fraction of \<30% * clinical evidence of primary hypothyroidism, primary subclinical hypothyroidism, or secondary hypothyroidism * history of stroke, transient ischemic attack, or peripheral artery disease within 24 weeks of first dose * history of bleeding diathesis or coagulopathy * current diagnosis of nephrotic syndrome * eligible to receive any commercially available fda-approved therapeutic for treatment of fcs unless proven to be ineffective or judged inappropriate by the treating physician note: additional inclusion/exclusion criteria may apply per protocol
efficacy of duloxetine compared to nsiads in osteoarthritis of knee

Conditions: Osteo Arthritis Knee

Summary: osteoarthritis (oa) is the most common degenerative joint disease, affecting more than 25% of the population . knee oa is an insidious disease related to structural changes in the joint over many years. progressive articular damage results in a loss of the extracellular matrix of cartilage in addition to changes in subchondral bone. duloxetine, a selective serotonin, and norepinephrine reuptake inhibitor, it seems to be effective in treating neuropathic and chronic pain conditions.

this will be a 13-week a randomized open labelled clinical trail in iraqi kurdistan region, that will be designed to assess the efficacy of duloxetine tablet compared with other group (nonsteroidal anti-inflammatory) drug on the reduction of pain caused by osteoarthritis of the knee. patients will be divided into two groups, first group (case) will receive duloxetine tablet 30mg for two weeks then titrated up to duloxetine 30mg bid. patients will be instructed to take the medication with meals. patients will be observed at visits (0) baseline then at second visits at 13 weeks then will be compared to control group that will receive nsaid (nonsteroidal anti-inflammatory drug) at baseline (0) visit then 2nd visits at 13 weeks.

Eligibility criteria:
inclusion criteria: 1. \> 40years of age 2. both genders 3. who will meet the american college of rheumatology clinical and radiographic criteria for the diagnosis of osteoarthritis of the knee 4. with pain for ≥14days of each separate month for 3months before study entry, with a mean score ≥4 on the 24-h average pain score (0-10) using the average of daily ratings exclusion criteria: 1. if they have diagnosed with inflammatory arthritis or an autoimmune disease 2. if they received invasive therapy in last 3 months (knee arthroscopy) or knee replacement at any time 3. patients with psychiatric disorders 4. hypertension 5. heart disease 6. patients on antipsychotics or anti-depressant -

Keywords: duloxetine, osteoarthritis, kurdistan region
is conventional tr band deflation protocol inferior to internationally developed tr band removal protocol in reducing occurrence of radial artery occlusion

Conditions: Radial Artery Occlusion

Summary: coronary artery disease (cad) is one of the major health concerns among other non-communicable diseases globally. cardiac catheterization is a diagnostic gold standard to determine the extent of disease in coronary arteries due to atherosclerosis. among the two approaches for cardiac catheterization, trans-radial approach has gained more popularity than conventional trans-femoral approach over the past decade with availability of compression devices for radial artery that assures lesser risk of bleeding and hematoma and has translated into increased patient comfort and early mobility post procedure. radial artery occlusion is a common complication of trans-radial procedures often ignored by the operator after procedure due to dual blood supply by ulnar artery. although clinically silent usually, it necessitate the need of monitoring radial artery for patency because of risk of limited trans-radial access later.reportedly, rao occurs in about 10% of cardiac catheterizations. , compression devices applied after sheath removal may be a contributing factor to radial artery occlusion because of selective pressure for extended time duration (3-4 hours). various protocols have been developed to remove tr band by different institutions across the globe and have been tested to assess post procedure complications. to the best of what we know, there exists no standard protocol to deflate tr band. also, the current protocol in practice at our institution has not been evaluated against other protocols that are followed in other institution across the globe claiming lesser post procedure complications. hence, our aim was to test through a randomized trial whether our hospital standard protocol is non-inferior to the existing international protocol of cohen \& alfonso that promises lesser complication rate


Eligibility criteria:
inclusion criteria: * patients admitted for coronary angiography in specified period of study * patients who sign informed consent exclusion criteria: * known radial artery occlusion * \> 3 radial angiograms in the past * plan for ad- hoc pci * on warfarin therapy * known bleeding diathesis or hypercoagulable state * contraindication to radial artery access such as hemodialysis fistula, mastectomy or localized infection

Keywords: radial artery occlusion tr band transradial catheterization
tocopherol is a novel treatment for cancer related mucositis

Conditions: Oral Mucositis

Summary: the present protocol is an attempt to prevent/treat mucositis in highly susceptible patients subjected to maximally tolerated doses of subsequently-myeloablative or myeloablative doses of chemoradiotherapy supported by autologous or allogeneic stem cell transplantation at the department of bone marrow transplantation. mucositis is a major problem in the management of transplant recipients which subjects the patients to the risk of sepsis, need for parenteral nutrition and need of narcotics. we are planning a 2 arm study, comparing 2 safe vitamin e based formulations with placebo.


Eligibility criteria:
inclusion criteria: * males and non-pregnant and non-lactating females, 18 years of age or older at the time of screening, who are to receive myeloablative agonists with or without total body irradiation (tbi) in preparation for either allogeneic or autologous hsct. patients who are to be hospitalized and are expected to remain hospitalized until marrow recovery. * karnofsky performance status of 60 or greater or ecog performance status of 2 or less. * normal dental examination as assessed by the investigator. exclusion criteria: * clinically significant acute and active oral cavity infection. * patients taking any investigational or other non-approved oral therapy for oral mucositis. * known hypersensitivity to vitamin e.